Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma.

被引：1
|
作者：
Siegel, Abby B.
El-Khoueiry, Anthony B.
Finn, Richard S.
Guthrie, Katherine
Venook, Alan P.
Blanke, Charles David
Brown, Robert S.
机构：
[1] Columbia Univ, New York, NY USA
[2] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[3] Univ Calif Los Angeles, Los Angeles, CA USA
[4] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[5] Univ Calif San Francisco, San Francisco, CA 94143 USA
[6] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
10.1200/jco.2015.33.3_suppl.401
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
401
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Sorafenib As Adjuvant Therapy For High-Risk Hepatocellular Carcinoma in Liver Transplant Recipients: Feasibility and Efficacy
    Saab, Sammy
    McTigue, Michael
    Finn, Richard S.
    Busuttil, Ronald W.
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2010, 8 (04) : 307 - 313
  • [22] High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation
    Staufer, Katharina
    Fischer, Lutz
    Seegers, Barbara
    Vettorazzi, Eik
    Nashan, Bjoern
    Sterneck, Martina
    TRANSPLANT INTERNATIONAL, 2012, 25 (11) : 1158 - 1164
  • [23] A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation
    Malin Sternby Eilard
    Mats Andersson
    Peter Naredi
    Charalampos Geronymakis
    Per Lindnér
    Christian Cahlin
    William Bennet
    Magnus Rizell
    BMC Cancer, 19
  • [24] A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation
    Eilard, Malin Sternby
    Andersson, Mats
    Naredi, Peter
    Geronymakis, Charalampos
    Lindner, Per
    Cahlin, Christian
    Bennet, William
    Rizell, Magnus
    BMC CANCER, 2019, 19 (1)
  • [25] Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
    Furuse, J.
    Ishii, H.
    Nakajima, K.
    Nakachi, K.
    Suzuki, E.
    Yoshino, M.
    EJC SUPPLEMENTS, 2006, 4 (12): : 114 - 114
  • [26] Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
    Furuse, Junji
    Ishii, Hiroshi
    Nakachi, Kohei
    Suzuki, Eiichiro
    Shimizu, Satoshi
    Nakajima, Keiko
    CANCER SCIENCE, 2008, 99 (01) : 159 - 165
  • [27] Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation
    de'Angelis, Nicola
    Landi, Filippo
    Nencioni, Marco
    Palen, Anais
    Lahat, Eylon
    Salloum, Chady
    Compagnon, Philippe
    Lim, Chetana
    Costentin, Charlotte
    Calderaro, Julien
    Luciani, Alain
    Feray, Cyrille
    Azoulay, Daniel
    PROGRESS IN TRANSPLANTATION, 2016, 26 (04) : 348 - 355
  • [28] Clinical predictors of response to sorafenib in patients with hepatocellular carcinoma.
    Marinelli, Sara
    Granito, Alessandro
    Terzi, Eleonora
    Leoni, Simona
    Piscaglia, Fabio
    Venerandi, Laura
    Bolondi, Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Improvement of results of liver transplantation for hepatocellular carcinoma.
    Onaca, N
    Davis, GL
    Jennings, LW
    Goldstein, RM
    Klintmalm, GB
    LIVER TRANSPLANTATION, 2005, 11 (07) : C62 - C62
  • [30] High pathological risk of recurrence after surgical resection for hepatocellular carcinoma. An indication for liver transplantation
    Sala, M
    Fuster, J
    Llovet, JM
    Garcia-Valdecasas, JC
    Navasa, M
    Varela, M
    Sole, M
    Rimola, A
    Rodes, J
    Bruix, J
    LIVER TRANSPLANTATION, 2003, 9 (06) : C32 - C32
12345